Vox Markets Logo

AstraZeneca's Imfinzi gets EU green light

07:53, 4th July 2025
Vox News
Company News
TwitterFacebookLinkedIn

Drugmaker AstraZeneca Plc   Follow | AZN said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer.
AZN said the European Commission's approval of Imfinzi was based on positive Phase III trial results, which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death when used in combination with gemcitabine and cisplatin as neoadjuvant treatment, versus neoadjuvant chemotherapy alone.

Dave Fredrickson, executive vice president of AstraZeneca's oncology haematology unit, said: "Imfinzi is poised to transform the standard of care for muscle-invasive bladder cancer in Europe as the first and only perioperative immunotherapy for these patients. In the NIAGARA Phase III trial, more than 80 per cent of patients were still alive two years after treatment with the Imfinzi regimen, setting a new survival benchmark for a disease that has seen few treatment advances in decades."

The FTSE 100-listed group noted that Imfinzi, which has already received US approval, was "generally well tolerated", and no new safety signals were observed in the neoadjuvant and adjuvant settings.

 

 

Reporting by Iain Gilbert at Sharecast.com

Stock Chart | AZN
TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Watchlist